Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C
Open accessThe DOI matches its Crossref record; 43 of the 45 references it cites were found in a registry or an index.
Abstract
NAFLD (non-alcoholic fatty liver disease) is one of the most frequent chronic liver diseases worldwide. The metabolic factors associated with NAFLD are also determinants of liver disease progression in chronic HCV (hepatitis C virus) infection. It has been reported that, besides inducing hepatic fatty acid biosynthesis, LXR (liver X receptor) regulates a set of inflammatory genes. We aimed to evaluate the hepatic expression of LXRα and its lipogenic and inflammatory targets in 43 patients with NAFLD, 44 with chronic HCV infection and in 22 with histologically normal liver. Real-time PCR and Western blot analysis were used to determine hepatic expression levels of LXRα and related lipogenic and inflammatory mediators in the study population. We found that the LXRα gene and its lipogenic targets PPAR-γ (peroxisome-proliferator-activated receptor-γ), SREBP (sterol-regulatory-element-binding protein)-1c, SREBP-2 and FAS (fatty acid synthase) were overexpressed in the liver of NAFLD and HCV patients who had steatosis. Moreover, up-regulation of inflammatory genes, such as TNF (tumour necrosis factor)-α, IL (interleukin)-6, OPN (osteopontin), iNOS (inducible NO synthase), COX (cyclo-oxygenase)-2 and SOCS (suppressors of cytokine signalling)-3, was observed in NAFLD and HCV patients. Interestingly, TNF-α, IL-6 and osteopontin gene expression was lower in patients with steatohepatitis than in those with steatosis. In conclusion, hepatic expression of LXRα and its related lipogenic and inflammatory genes is abnormally increased in NAFLD and HCV patients with steatosis, suggesting a potential role of LXRα in the pathogenesis of hepatic steatosis in these chronic liver diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The increase in DNL, often observed in metabolic diseases, is also due to the overactivation of the transcription factors that stimulate DNL, e.g. sterol regulatory element-binding protein-1c (SREBP-1c) and carbohydrate-responsive-element-binding-protein (ChREBP), which can promote the development of MASLD.”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [28]
In the citing paper
“In fact, LXR is a cholesterol sensor, with a central role in the inflammatory control and in the regulation of lipid and glucose metabolism, overexpressed in case of hepatic steatosis [125].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [125]
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Repa, J. J., Liang, G., Ou, J., Bashmakov, Y., Lobaccaro, J.-M. A., Shimomura, I., Shan, B., Brown, M. S., Goldstein, J. L., & Mangelsdorf, D. J. (2000) · Genes & Development · doi:10.1101/gad.844900 · Cited by 1,692
Classification of chronic viral hepatitis: a need for reassessment
Scheuer, P. J. (1991) · Journal of Hepatology · doi:10.1016/0168-8278(91)90084-o · Cited by 1,576
Reciprocal regulation of inflammation and lipid metabolism by liver X receptors
Joseph, S. B., Castrillo, A., Laffitte, B. A., Mangelsdorf, D. J., & Tontonoz, P. (2003) · Nature Medicine · doi:10.1038/nm820 · Cited by 1,158
LXR, a nuclear receptor that defines a distinct retinoid response pathway.
Willy, P. J., Umesono, K., Ong, E. S., Evans, R. M., Heyman, R. A., & Mangelsdorf, D. J. (1995) · Genes & Development · doi:10.1101/gad.9.9.1033 · Cited by 1,123
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077
Beyond insulin resistance in NASH: TNF-α or adiponectin?
Hui, J. M., Hodge, A., Farrell, G. C., Kench, J. G., Kriketos, A., & George, J. (2004) · Hepatology · doi:10.1002/hep.20280 · Cited by 942
Feldstein, A. E., Werneburg, N. W., Canbay, A., Guicciardi, M. E., Bronk, S. F., Rydzewski, R., Burgart, L. J., & Gores, G. J. (2004) · Hepatology · doi:10.1002/hep.20283 · Cited by 834
Joseph, S. B., Laffitte, B. A., Patel, P. H., Watson, M. A., Matsukuma, K. E., Walczak, R., Collins, J. L., Osborne, T. F., & Tontonoz, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111041200 · Cited by 779
CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis
Leclercq, I. A., Farrell, G. C., Field, J., Bell, D. R., Gonzalez, F. J., & Robertson, G. R. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8814 · Cited by 764
The Role of Orphan Nuclear Receptors in the Regulation of Cholesterol Homeostasis
Repa, J. J., & Mangelsdorf, D. J. (2000) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.16.1.459 · Cited by 759
The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease
McCullough, A. J. (2004) · Clinics in Liver Disease · doi:10.1016/j.cld.2004.04.004 · Cited by 580
Day, C. P. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.017 · Cited by 395
Ueki, K., Kondo, T., Tseng, Y.-H., & Kahn, C. R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402511101 · Cited by 384
PPARγ2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes
Schadinger, S. E., Bucher, N. L. R., Schreiber, B. M., & Farmer, S. R. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00513.2004 · Cited by 376
Yoshikawa, T., Ide, T., Shimano, H., Yahagi, N., Amemiya-Kudo, M., Matsuzaka, T., Yatoh, S., Kitamine, T., Okazaki, H., Tamura, Y., et al. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0190 · Cited by 297
Higuchi, N., Kato, M., Shundo, Y., Tajiri, H., Tanaka, M., Yamashita, N., Kohjima, M., Kotoh, K., Nakamuta, M., Takayanagi, R., et al. (2008) · Hepatology Research · doi:10.1111/j.1872-034x.2008.00382.x · Cited by 286
Garcia-Monzón, C., Martín-Pérez, E., Iacono, O. L., Fernández-Bermejo, M., Majano, P. L., Apolinario, A., Larrañaga, E., & Moreno-Otero, R. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80301-3 · Cited by 265
Self-citationHepatitis C virus infection: Molecular pathways to metabolic syndrome
Sheikh, M. Y., Choi, J., Qadri, I., Friedman, J. E., & Sanyal, A. J. (2008) · Hepatology · doi:10.1002/hep.22269 · Cited by 240
Nonalcoholic Steatohepatitis and the Metabolic Syndrome
Neuschwander-Tetri, B. A. (2005) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200512000-00011 · Cited by 197
Critical role of PA28γ in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis
Moriishi, K., Mochizuki, R., Moriya, K., Miyamoto, H., Mori, Y., Abe, T., Murata, S., Tanaka, K., Miyamura, T., Suzuki, T., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607312104 · Cited by 194
Sahai, A., Malladi, P., Melin-Aldana, H., Green, R. M., & Whitington, P. F. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00002.2004 · Cited by 181
Wójcicka, G., Jamróz-Wiśniewska, A., Horoszewicz, K., & Bełtowski, J. (2007) · PubMed · Cited by 179
Mitsuyoshi, H., Yasui, K., Harano, Y., Endo, M., Tsuji, K., Minami, M., Itoh, Y., Okanoue, T., & Yoshikawa, T. (2009) · Hepatology Research · doi:10.1111/j.1872-034x.2008.00464.x · Cited by 172
Martínez, Ó. N., Fernández-Martínez, A., Majano, P. L., Apolinario, A., Gómez-Gonzalo, M., Benedicto, I., López-Cabrera, M., Boscá, L., Clemente, G., García-Monzón, C., et al. (2004) · Gut · doi:10.1136/gut.2003.038364 · Cited by 171
Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat?
Larter, C. Z., & Farrell, G. C. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.11.030 · Cited by 169
Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data
Negro, F., & Sanyal, A. J. (2009) · Liver International · doi:10.1111/j.1478-3231.2008.01950.x · Cited by 169
Hepatitis C and steatosis: a reappraisal
Lonardo, A., Loria, P., Adinolfi, L. E., Carulli, N., & Ruggiero, G. (2005) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2005.00669.x · Cited by 156
Oem, J., Jackel‐Cram, C., Li, Y.-P., Zhou, Y., Zhong, J., Shimano, H., Babiuk, L. A., & Liu, Q. (2008) · Journal of General Virology · doi:10.1099/vir.0.83491-0 · Cited by 114
García‐Monzón, C., Majano, P. L., Zubia, I., Sanz, P., Apolinario, A., & Moreno‐Otero, R. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80080-x · Cited by 105
Self-citationOgawa, D., Stone, J. F., Takata, Y., Blaschke, F., Chu, V. H., Towler, D. A., Law, R. E., Hsueh, W. A., & Bruemmer, D. (2005) · Circulation Research · doi:10.1161/01.res.0000163630.86796.17 · Cited by 104
García‐Mediavilla, M. V., Sánchez‐Campos, S., González-Pérez, P., Gómez-Gonzalo, M., Majano, P. L., López‐Cabrera, M., Clemente, G., García‐Monzón, C., & González‐Gallego, J. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.04.019 · Cited by 94
Self-citationPersico, M., Capasso, M., Russo, R., Persico, E., Crocè, L. S., Tiribelli, C., & Iolascon, A. (2007) · Gut · doi:10.1136/gut.2007.129478 · Cited by 88
Kim, T.-H., Kim, H., Park, J.-M., Im, S.-S., Bae, J.-S., Kim, M.-Y., Yoon, H.-G., Cha, J.-Y., Kim, K.-S., & Ahn, Y.-H. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.006742 · Cited by 86
GOCHEE, P. A., JONSSON, J. R., CLOUSTON, A. D., PANDEYA, N., PURDIE, D. M., & POWELL, E. E. (2003) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2003.02984.x · Cited by 78
Impact of cholesterol metabolism and the LXRα-SREBP-1c pathway on nonalcoholic fatty liver disease
Enjoji (2009) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000170 · Cited by 78
Wang, Y. Y., Dahle, M. K., Ågren, J., Myhre, A. E., Reinholt, F. P., Foster, S. J., Collins, J. L., Thiemermann, C., Aasen, A. O., & Wang, J. E. (2006) · Shock · doi:10.1097/01.shk.0000191377.78144.d9 · Cited by 76
Nontriglyceride Hepatic Lipotoxicity: The New Paradigm for the Pathogenesis of NASH
Neuschwander‐Tetri, B. A. (2010) · Current Gastroenterology Reports · doi:10.1007/s11894-009-0083-6 · Cited by 68
Yang, X., Schaper, F., Teubner, A., Lammert, F., Heinrich, P. C., Matern, S., & Siewert, E. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.02.048 · Cited by 46
Cyclooxygenase‐2 Expression in Chronic Liver Diseases and Hepatocellular Carcinoma
Giannitrapani, L., Ingrao, S., Soresi, M., Florena, A. M., Spada, E. L., Sandonato, L., D’Alessandro, N., Cervello, M., & Montalto, G. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.03698.x · Cited by 46
Cited by
Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
Smith, G. I., Shankaran, M., Yoshino, M., Schweitzer, G. G., Chondronikola, M., Beals, J. W., Okunade, A. L., Patterson, B. W., Nyangau, E., Field, T., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134165 · Cited by 771
“Hepatic expression of SREBP-1c, ChREBP and other genes involved in lipogenesis are increased in people with hepatic steatosis compared with those who have normal IHTG content (40-44).”
BackgroundPorras, D., Nistal, E., Martínez-Flórez, S., Pisonero-Vaquero, S., Olcoz, J. L., Jover, R., González-Gallego, J., García-Mediavilla, M. V., & Sánchez-Campos, S. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.11.037 · Cited by 524
“development by enhancing lipogenesis in in vivo and in vitro models and in the liver of patients [5, 34].”
BackgroundSelf-citationPast, present and future perspectives in nonalcoholic fatty liver disease
Sanyal, A. J. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0144-8 · Cited by 522
Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis
Musso, G., Gambino, R., & Cassader, M. (2013) · Progress in Lipid Research · doi:10.1016/j.plipres.2012.11.002 · Cited by 409
Molecular pathways in non-alcoholic fatty liver disease
Auguet, T., Berlanga, A., Guiu-Jurado, E., & Porras, J. A. (2014) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s62831 · Cited by 379
Metadata
- Authors
- Lima-Cabello, E., García-Mediavilla, M. V., Miquilena-Colina, M. E., Vargas-Castrillón, J., Lozano-Rodríguez, T., Fernández-Bermejo, M., Olcoz, J. L., González-Gallego, J., García-Monzón, C., & Sánchez-Campos, S.
- Affiliations
- Institute of Biomedicine (IBIOMED), University of León, León, Spain
- Instituto de Salud Carlos III (ES)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain
- Gastroenterology Service, San Pedro de Alcántara Hospital, Cáceres, Spain
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2010-12-03
- Volume
- 120
- Issue
- 6
- Pages
- 239-250
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- OpenAlex
- W2005558543
- Cited by
- 144
- References
- 45
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 6 · 2023: 7 · 2022: 5 · 2021: 10 · 2020: 8 · 2019: 8 · 2018: 5 · 2017: 11 · 2016: 11 · 2015: 17 · 2014: 17 · 2013: 11 · 2012: 12
- FWCI
- 6.74
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-06-19)
- Open access
- bronze
- doi.org
- Locations
- Clinical Science (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Trinity's Access to Research Output (TARA) (Trinity College Dublin) (submittedVersion)
- Funders
- Fundación Eugenio Rodríguez Pascual
- Junta de Castilla y León
- Instituto de Salud Carlos III
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- non-alcoholic fatty liver disease, hepatitis C, liver X receptor alpha, hepatic steatosis, steatohepatitis, pro-inflammatory gene expression, lipogenic genes, PPARγ, SREBP-1c, SREBP2, fatty acid synthase, TNF-α, interleukin-6, osteopontin, inducible nitric oxide synthase, cyclooxygenase-2, liver inflammation
- MeSH terms
- Liver X Receptors, Adult, Fatty Liver, Female, Gene Expression Regulation, Humans, Liver, Male, Middle Aged, Up-Regulation, Oxidative Stress, Inflammation Mediators, Hepatitis C, Chronic, Lipogenesis, Orphan Nuclear Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.